Doschemen Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 05-12-2024
- Paid Up Capital ₹ 0.60 M
as on 05-12-2024
- Company Age 10 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -7.28%
(FY 2022)
- Profit 52.21%
(FY 2022)
- Ebitda 102.49%
(FY 2022)
- Net Worth -22.64%
(FY 2022)
- Total Assets 5.51%
(FY 2022)
About Doschemen Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.60 M, as per Ministry of Corporate Affairs (MCA) records.
Devender Singh and Tarvindar Kaur serve as directors at the Company.
- CIN/LLPIN
U74999DL2014PTC271224
- Company No.
271224
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Sep 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Doschemen Pharmaceuticals Private Limited offer?
Doschemen Pharmaceuticals Private Limited offers a wide range of products and services, including Antibacterial Drugs, Antibiotic Medicine.
Who are the key members and board of directors at Doschemen Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Devender Singh  | Director | 03-Sep-2014 | Current |
| Tarvindar Kaur | Director | 03-Sep-2014 | Current |
Financial Performance and Corporate Structure Insights of Doschemen Pharmaceuticals.
Doschemen Pharmaceuticals Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 7.28% decrease. The company also saw a substantial improvement in profitability, with a 52.21% increase in profit. The company's net worth observed a substantial decline by a decrease of 22.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Doschemen Pharmaceuticals?
In 2022, Doschemen Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Surendra Consultancy Services Private LimitedActive 20 years 9 monthsDevender Singh and Tarvindar Kaur are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Doschemen Pharmaceuticals?
Unlock and access historical data on people associated with Doschemen Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Doschemen Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Doschemen Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
